Genmab A/S (GMABN)
XMEX 
Summary
GMABN Chart
Genmab: Epkinly Shines In Phase 3 DLBCL Trial
Genmab delivered strong topline results for Epkinly in frontline DLBCL, showing a 51% reduction in risk of progression or death. Epkinly's efficacy notably exceeds Roche's Polivy in similar settings, positioning GMAB as a potential market leader among T-cell engagers. Frontline DLBCL represents the key growth driver for Epkinly, and I see upside to the company's $3 billion+ peak sales guidance based on better-than-expected treatment effect.
Strength Seen in Genmab (GMAB): Can Its 10.7% Jump Turn into More Strength?
Genmab (GMAB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Genmab Shares Climb After Positive Study Results for Blood-Cancer Drug
The Danish company said the Epkinly drug helped extend the time patients with a common type of lymphoma lived.
Genmab A/S (GMABN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Genmab A/S ever had a stock split?
Genmab A/S Profile
| Biotechnology Industry | Healthcare Sector | Jan van de Winkel CEO | XMEX Exchange | US3723032062 ISIN |
| DK Country | 3,119 Employees | - Last Dividend | 1 May 2018 Last Split | - IPO Date |
Overview
Genmab A/S is a pioneering biotechnology company based in Copenhagen, Denmark, specializing in the development of antibody therapeutics for the treatment of cancer and other serious diseases. Founded in 1999, Genmab has grown to become a leader in the field, leveraging its expertise to market innovative treatments worldwide. The company's therapeutic products focus on employing human monoclonal antibodies to target and combat diseases, with a strong emphasis on hematological malignancies and solid tumors. Genmab's strategic collaborations with industry leaders like Seagen Inc., argenx, AbbVie, BioNTech, Janssen, and Novo Nordisk A/S play a pivotal role in expanding its portfolio and enhancing therapeutic development.
Products and Services
- DARZALEX: A human monoclonal antibody indicated for the treatment of patients with multiple myeloma (MM), DARZALEX has shown significant efficacy in improving patient outcomes.
- Teprotumumab: This therapeutic agent is used for the treatment of thyroid eye disease, showcasing Genmab's ability to address rare and severe conditions.
- Amivantamab: Designed for patients with advanced or metastatic gastric or esophageal cancer and non-small cell lung cancer (NSCLC), Amivantamab illustrates Genmab's focus on solid tumors.
- Daratumumab: Beyond its use in MM treatment, daratumumab is explored for non-MM blood cancers and AL amyloidosis, underscoring its versatile potential in hematological conditions.
- GEN1047, Tisotumab Vedotin, DuoBody-PD-L1x4-1BB, DuoBody-CD40x4-1BB, Epcoritamab, HexaBody-CD38, and GEN3017: These diverse therapeutic candidates are at various stages of development for treating conditions such as cervical, ovarian, and solid cancers, hematological malignancies, relapsed/refractory diffuse large B-cell lymphoma, and chronic lymphocytic leukemia. Each represents Genmab's commitment to expanding its portfolio across a wide range of cancers.
- Inclacumab: Currently in a Phase 3 trial for vaso-occlusive crises, Inclacumab exemplifies Genmab's venture into non-cancerous disorders, providing potential new treatments for conditions with substantial unmet needs.
- Camidanlumab Tesirine: A candidate for treating Hodgkin lymphoma and solid tumors, highlighting the company's ongoing efforts in targeting both hematologic cancers and solid tumors.
- JNJ-64007957 and JNJ-64407564: These antibodies are in development for multiple myeloma treatment, illustrating ongoing innovation in this challenging therapeutic area.
- PRV-015: For treating celiac disease, PRV-015 demonstrates Genmab's ability to apply its antibody expertise beyond oncology, addressing autoimmune conditions.
- Mim8: A candidate for hemophilia A treatment, showcasing Genmab's commitment to improving the quality of life for patients with blood disorders.
- Lu AF82422: In development for multiple system atrophy disease, Lu AF82422 represents Genmab's research into neurodegenerative disorders, expanding the company's therapeutic reach.
Contact Information
